What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Schizophrenia
- Psychiatry
Robert W. Buchanan mainly investigates Psychosis, Schizophrenia, Psychiatry, Neuroscience and Schizophrenia.
His Psychosis research integrates issues from Internal medicine, Clinical trial, Nicotinic agonist and Nosology.
His work carried out in the field of Schizophrenia brings together such families of science as Clinical psychology, Cognition, Cognitive disorder and Audiology.
His work on Psychiatry is being expanded to include thematically relevant topics such as Psychometrics.
His Schizophrenia research includes themes of Psychotherapist, Psychosocial and Outcomes research.
His Clozapine research incorporates themes from Pharmacotherapy, Quality of life and Antipsychotic.
His most cited work include:
- The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements (659 citations)
- The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. (656 citations)
- The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003 (626 citations)
What are the main themes of his work throughout his whole career to date?
Robert W. Buchanan mainly focuses on Schizophrenia, Psychiatry, Psychosis, Internal medicine and Schizophrenia.
His Schizophrenia research is multidisciplinary, relying on both Placebo, Cognition and Clinical psychology.
His Psychiatry research includes elements of Clinical trial and Randomized controlled trial.
He has researched Psychosis in several fields, including Psychopathology, Neuroscience, Psychometrics and Audiology.
The concepts of his Internal medicine study are interwoven with issues in Extrapyramidal symptoms, Endocrinology and Olanzapine.
The Schizophrenia study combines topics in areas such as Psychotherapist and Cognitive psychology.
He most often published in these fields:
- Schizophrenia (48.34%)
- Psychiatry (39.58%)
- Psychosis (30.82%)
What were the highlights of his more recent work (between 2014-2021)?
- Schizophrenia (48.34%)
- Clinical psychology (19.03%)
- Psychiatry (39.58%)
In recent papers he was focusing on the following fields of study:
Schizophrenia, Clinical psychology, Psychiatry, Cognition and Clinical trial are his primary areas of study.
His study in Schizophrenia focuses on Schizoaffective disorder in particular.
His Clinical psychology research incorporates themes from Psychosis, Social skills, Social cognition, Neurocognitive and Oxytocin.
His work carried out in the field of Psychosis brings together such families of science as Valence, Arousal, Mental representation, Social perception and Developmental psychology.
His studies in Clinical trial integrate themes in fields like Psychometrics, Perception, Schizophrenia, Text mining and Psychosis risk.
His Internal medicine research is multidisciplinary, relying on both Clozapine and Brief Psychiatric Rating Scale.
Between 2014 and 2021, his most popular works were:
- Negative symptoms of schizophrenia: new developments and unanswered research questions (95 citations)
- Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms (70 citations)
- Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. (54 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Schizophrenia
- Psychiatry
His primary scientific interests are in Schizophrenia, Psychiatry, Clinical psychology, Clinical trial and Cognition.
His work blends Schizophrenia and Future studies studies together.
Much of his study explores Psychiatry relationship to Association.
His Clinical psychology research is multidisciplinary, incorporating perspectives in Apathy, Psychiatric status rating scales, Psychosis and Social cognition.
His Clinical trial study combines topics from a wide range of disciplines, such as Evidence-based practice, Psychometrics, Perception and Psychosis risk.
His studies examine the connections between Antipsychotic and genetics, as well as such issues in Internal medicine, with regards to Clozapine, Scale for the Assessment of Negative Symptoms and Brief Psychiatric Rating Scale.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
